Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 85/100

Termination Rate

14.3%

1 terminated out of 7 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

5Total
Not Applicable (2)
P 1 (2)
P 2 (1)

Trial Status

Unknown2
Enrolling By Invitation2
Terminated1
Active Not Recruiting1
Withdrawn1

Clinical Trials (7)

Showing 7 of 7 trials
NCT05287737Enrolling By InvitationPrimary

Clinical Outcome After Total Pancreatectomy With Islet Autotransplantation

NCT05540197Enrolling By InvitationPrimary

Arginine-stimulated Indication of Early Outcome After Islet Transplantation

NCT02803905Phase 2Active Not RecruitingPrimary

Islet Transplant Alone in OMENtum

NCT00579371Phase 1TerminatedPrimary

Cadaveric Islet Transplantation in Patients With Insulin-Dependent Diabetes Mellitus

NCT04884633Not ApplicableUnknownPrimary

Novel Method of Pancreatic Islet Transplantation Into the Omentum

NCT01033500Not ApplicableWithdrawnPrimary

Calcineurin Inhibitor-free, Steroid-free Immunosuppressive Regimen in Simultaneous Islet-Kidney Transplantation for Uremic Type 1 Diabetic Patients

NCT00008801Phase 1Unknown

hOKT3gamma1 (Ala-Ala) for the Prevention of Human Islet Allograft Failure

Showing all 7 trials

Research Network

Activity Timeline